You are here

CLL

ASCO: BMS pitches Breyanzi as the first CAR-T for CLL. But will a single-arm trial persuade the FDA?

ASCO: BMS pitches Breyanzi as the first CAR-T for CLL. But will a single-arm trial persuade the FDA?

Fierce Pharma

Bristol Myers Squibb

clinical trials

Flag link:

Secura Bio to keep offering blood cancer drug despite negative ODAC vote, OS questions

Secura Bio to keep offering blood cancer drug despite negative ODAC vote, OS questions

Endpoints

small lymphocytic lymphoma

Flag link:

Bristol Myers claims win with CAR-T therapy Breyanzi in leukemia

Bristol Myers claims win with CAR-T therapy Breyanzi in leukemia

Endpoints

Bristol Myers Squibb

Flag link:

BeiGene's Brukinsa wins CLL approval after topping Imbruvica in head-to-head trial

BeiGene's Brukinsa wins CLL approval after topping Imbruvica in head-to-head trial

Endpoints

Flag link:

TG slips out a nasty surprise for investors

TG slips out a nasty surprise for investors

EP Vantage

TG Therapeutics

Flag link:

Novartis-backed Penn study proposes boosting CAR-T responses in CLL by waking up 'war weary' T cells

Novartis-backed Penn study proposes boosting CAR-T responses in CLL by waking up 'war weary' T cells

Fierce Biotech

Flag link:

BeiGene tees up 3-way leukemia competition against J&J-AbbVie, AstraZeneca with Brukinsa win

BeiGene tees up 3-way leukemia competition against J&J-AbbVie, AstraZeneca with Brukinsa win

Fierce Pharma

small lymphocytic lymphoma

clinical trials

Flag link:

In next-gen BTK battle, AbbVie and J&J tout pivotal data backing Imbruvica as a combo treatment

In next-gen BTK battle, AbbVie and J&J tout pivotal data backing Imbruvica as a combo treatment

Endpoints

clinical trials

Flag link:

AstraZeneca Redefining Cancer Care in Breast Cancer, Leukemia at ASCO

AstraZeneca Redefining Cancer Care in Breast Cancer, Leukemia at ASCO

BioSpace

Flag link:

TG Therapeutics completes FDA filing for Roche challenger in CLL

TG Therapeutics completes FDA filing for Roche challenger in CLL

Pharmaforum

TG Therapeutics

ublituximab-umbralisib

Flag link:

AZ says Calquence is a safer drug than Imbruvica

AZ says Calquence is a safer drug than Imbruvica

Pharmaforum

Flag link:

TG Therapeutics set for upsized IPO to develop cancer combination drug

TG Therapeutics set for upsized IPO to develop cancer combination drug

Pharmaforum

TG Therapeutics

Flag link:

ASH: AstraZeneca's Calquence, BeiGene's Brukinsa turn heads with new data, putting Imbruvica on notice

ASH: AstraZeneca's Calquence, BeiGene's Brukinsa turn heads with new data, putting Imbruvica on notice

Fierce Pharma

Flag link:

Janssen gets expanded EC nod for blood cancer combo drug Imbruvica plus rituximab

Janssen gets expanded EC nod for blood cancer combo drug Imbruvica plus rituximab

Pharmaceutical Business Review

Flag link:

AbbVie, J&J blockbuster Imbruvica rakes in 11th FDA approval, as competitors work on eroding franchise

AbbVie, J&J blockbuster Imbruvica rakes in 11th FDA approval, as competitors work on eroding franchise

Endpoints

Flag link:

Janssen seeks EMA nod for Imbruvica, rituximab combo in previously untreated CLL

Janssen seeks EMA nod for Imbruvica, rituximab combo in previously untreated CLL

Pharmaceutical Business Review

Flag link:

Leukemia rivals try to stay ahead as Merck, Lilly chase

Leukemia rivals try to stay ahead as Merck, Lilly chase

Biopharma Dive

Flag link:

ASH: Eli Lilly plots 'ambitious' cancer program after sharing early BTK data

ASH: Eli Lilly plots 'ambitious' cancer program after sharing early BTK data

Fierce Biotech

Flag link:

ASH19: AZ’s Calquence throws gauntlet down to Imbruvica

ASH19: AZ’s Calquence throws gauntlet down to Imbruvica

Pharmaforum

Flag link:

ASH: AbbVie, Roche pad their case for fixed-duration Venclexta use in CLL

ASH: AbbVie, Roche pad their case for fixed-duration Venclexta use in CLL

Fierce Pharma

Flag link:

Pages